Results 61 to 70 of about 3,015 (158)

Sustained virological response 12 versus sustained virological response 24 as evaluation endpoints in chronic hepatitis C virus Egyptian patients treated with sofosbuvir-based regimens

The Egyptian Journal of Internal Medicine, 2019
Background The recommended reliance on 12 weeks posttreatment sustained virological response (SVR12) instead of SVR24 was validated for treatment evaluation. Aim Judging claimed concordance between SVR12 and SVR24.
Maha M Elsabaawy, Khalid Gameel, Heba Eldemerdash, Talaat Zakareia, Mahmoud Eltahawy, Marry Albert, Marwa Fekry, Enas Ouda, Helmy Elshazly, Ashraf Eljaky   +9 more
doaj   +1 more source

The impact of ribavirin on real-world adherence rates in hepatitis C patients treated with sofosbuvir plus simeprevir

ClinicoEconomics and Outcomes Research, 2015
David R Walker, Timothy R Juday, Shivaji R Manthena, Yonghua Jing, Vipan Sood Health Economics and Outcomes Research, AbbVie Inc., North Chicago, IL, USA Background: Combination therapy with sofosbuvir (SOF) and simeprevir (SIM) is used to treat ...
Walker DR, Juday TR, Manthena SR, Jing Y, Sood V   +4 more
doaj  

Quality of life of Brazilian chronic hepatitis C patients treated with interferon-free therapies

Revista do Instituto de Medicina Tropical de São Paulo, 2018
Due to the severity of chronic hepatitis C, there are multiple factors that can negatively affect the quality of life of infected patients. The aim of this study was to evaluate changes in the health-related quality of life (HRQoL) in patients under ...
Fabiane Mateus Siqueira, Vinicius Lins Ferreira, Helena Hiemisch Lobo Borba, Roberto Pontarolo   +3 more
doaj   +1 more source

Optimizing choice of oral interferon-free treatment for genotype 1 hepatitis C virus using testing for NS5A resistance: a cost-utility analysis from the perspective of the Italian National Health Service

ClinicoEconomics and Outcomes Research, 2017
Kirsten Y Westerhout,1 Walter Bouwmeester,1 Inge Duchesne,2 Marta Pisini,2 Marjanne A Piena,1 Francesco Damele,3 Beatrice Gueron,2 Maarten Treur,1 Jonathan Belsey4 1Pharmerit BV, Marten Meesweg, Rotterdam, the Netherlands; 2Janssen EMEA, Turnhoutseweg ...
Westerhout KY, Bouwmeester W, Duchesne I, Pisini M, Piena MA, Damele F, Gueron B, Treur M, Belsey J   +8 more
doaj  

Avances en hepatitis C

Revista del Hospital Italiano de Buenos Aires
La hepatitis C es la principal causa de hepatitis crónica, cirrosis y cáncer de hígado, así como la indicación más común de trasplante hepático en la Argentina y muchos otros países.
Ezequiel Mauro, Sebastián Marciano, Omar Galdame, Adrián Gadano   +3 more
doaj  

Hepatitis C Drugs: The End of the Pegylated Interferon Era and the Emergence of All-Oral, Interferon-Free Antiviral Regimens: A Concise Review

Canadian Journal of Gastroenterology and Hepatology, 2014
Between 2001 and 2011, the standard of care for chronic hepatitis C virus (HCV) infection was a combination of pegylated interferon (PEGIFN) and ribavirin (RBV).
Alan Hoi Lun Yau, Eric M Yoshida
doaj   +1 more source

Simeprevir

Reactions Weekly, 2015
  +6 more sources

Markedly Improved Glycemic Control in Poorly Controlled Type 2 Diabetes following Direct Acting Antiviral Treatment of Genotype 1 Hepatitis C

Case Reports in Hepatology, 2016
Type 2 diabetes mellitus (T2DM) is often associated with hepatitis C virus (HCV) infection. Successful HCV treatment may improve glycemic control and potentially induce remission of T2DM. We report a case of an obese 52-year-old woman with mixed genotype
Raymond Anthony Pashun, Nicole T. Shen, Arun Jesudian   +2 more
doaj   +1 more source

Perfil dos primeiros pacientes com Hepatite C tratados com SIMEPREVIR na Bahia e os desfechos desta terapia

Jornal de Assistência Farmacêutica e Farmacoeconomia
Introdução: A infecção pelo vírus da hepatite C é um problema de saúde pública, afeta 2,3 milhões de pessoas no Brasil e é responsável por 75% dos óbitos por hepatites virais.
Jane Meire Magalhães Carneiro, Rosemeire Dourado Costa Fernandes, Mila Palma Pacheco, Maria Gleide Cunha Rodrigues, Christiane Vianna Cavalcante, Jorge Viana dos Santos, Marcia Cristina da Silva Ribeiro, Suzana Márcia Nascimento   +7 more
doaj   +1 more source

A simeprevir-inducible molecular switch for the control of cell and gene therapies. [PDF]

Nat Commun, 2023
Chin SE, Schindler C, Vinall L, Dodd RB, Bamber L, Legg S, Sigurdardottir A, Rees DG, Malcolm TIM, Spratley SJ, Granéli C, Sumner J, Tigue NJ.   +12 more
europepmc   +1 more source